Mr Annaswamy Vaidheesh is the Chairperson of the company with effect from 29th September 2023. As Chairperson, his primary responsibility is to oversee the company's overall business operations, reporting directly to the Board of Directors. Additionally, Mr Vaidheesh also serves as the Chairperson at Cohance Lifesciences Ltd.
Prior to his current roles, Mr Vaidheesh has amassed a wealth of experience in the industry. He has held significant positions, including the President of OPPI (Organization of Pharmaceutical Producers of India) and earlier was with J&J Asia Pacific in senior regional leadership positions Additionally, he has served as an Advent operating officer.
Mr Vaidheesh, a seasoned business leader with over 35 years of experience in the healthcare and FMCG sectors, actively employs process excellence and Six Sigma to drive operational efficiency. He imparts his business strategy and leadership ethics expertise and has been recognised with prestigious awards, solidifying his reputation as a highly respected and influential figure. His strategic prowess has led to impressive double-digit revenue and profit growth, and his commitment to positive change earns him admiration and respect from his peers in the industry.
Dr. V. Prasada Raju is the Company's Managing Director. He was appointed on 29th September 2023 as the Managing Director. He is responsible for the Company's overall business and reports to the Company's Board of Directors. Dr Raju concurrently holds the position of CEO at Cohance Lifesciences Ltd.
Dr Raju served as an Executive Director at Granules India Ltd., where he played a key role in driving growth strategy, managing the product portfolio, overseeing scientific and regulatory affairs, handling intellectual property matters, and leading new business initiatives. Moreover, he was instrumental in establishing R&D and Greenfield projects within the company. As part of his responsibilities, he served on the Boards of Granules Omnichem Pvt Ltd (Vizag, India), Granules Pharmaceuticals Inc. (DC, USA), and USpharma Ltd (FL, USA).
Dr Raju's impressive academic background includes a PhD in chemistry, a PG Dip in patent law, and specialised training in material sciences at IIT, Chicago, USA. He is also an alumnus of the Senior Management Program at IIMc (Indian Institute of Management). With over 30 years of techno-commercial experience in the pharmaceutical industry, spanning various aspects of the value chain, he has held leadership roles at Granules India Limited and Dr Reddy's Laboratories. During his tenure at Dr. Reddy's, from 1994 to 2012, he provided technical, strategic, and operational leadership in uniquely challenging positions within the pharma sector.
Overall, Dr V. Prasada Raju's extensive experience and expertise make him a highly respected and accomplished figure in the pharmaceutical industry, where he continues to make significant contributions in his current roles.
Mr Pankaj Patwari is a Non-Executive Director of the Company, effect from 29th September 2023. He is a Chartered Accountant by training and holds an MBA from the Indian Institute of Management (Lucknow).
As Managing Director - of Advent India PE Advisors Private Limited, he has managed Advent's investments in Manjushree Technopack Limited and Bharat Serums and Vaccines Limited (BSV). He has also been a Director at Manjushree Technopack Limited and Gokaldas Intimatewear Private Limited.
Having worked with Bain Capital before Advent for six years, Pankaj worked on several pharmaceutical and industrial transactions. Before his stint at Bain, Pankaj spent four years with McKinsey & Co., focusing primarily on financial services.
Mr. K G Ananthakrishnan is an Independent Director of the Company with effect from 29th September 2023. Throughout his illustrious career, Mr Ananthakrishnan has held influential positions, including Director General of the Organization of Pharmaceutical Producers of India (OPPI) and Co-Chair of the Pharma Committee at the Confederation of Indian Industry (CII), where he played a pivotal role in shaping vital policy initiatives.
Educationally, Mr Ananthakrishnan holds a Master's in Marketing Management from Jamnalal Bajaj Institute of Management Studies, Mumbai, and a Bachelor's in Science from Osmania University, Hyderabad. To further enhance his knowledge and skills, he has completed Executive Development Programs at the Wharton Business School, USA, and the Finance for Non-Finance Program at INSEAD, France.
With over 40 years of progressive leadership experience in the pharmaceutical market, Mr. Ananthakrishnan’s career began in 1976 with Novartis India Limited. He then held key positions at Pharmacia India, Pfizer India Ltd., and Fulford (India) Ltd. Notably, during his tenure as Vice President and Managing Director of the South Asia Region at MSD, he successfully transformed the company into a rapid-growth pharmaceutical powerhouse.
Ms Matangi Gowrishankar is an Independent Director of the Company with effect from 29th September 2023. She is a distinguished expert, serving as a Strategic Advisor, Certified Coach, and Catalyst for change. Prior to her current role, Ms Gowrishankar held the esteemed position of BP's Global Head of Capability Development, where she played a crucial role in enhancing the organisation's talent capabilities and driving leadership excellence.
With over 40 years of experience working with senior leadership teams, Ms Matangi Gowrishankar brings knowledge and insights to support organisations' growth and transformation endeavours. Her extensive Business and Human Resources professional background has provided her invaluable global exposure and a deep understanding of various leadership aspects.
Having closely collaborated with Senior Leadership teams, Ms Gowrishankar possesses valuable expertise in emerging skills such as Contemporary Leadership, Leading in a digitally enabled world, and leadership transformation. She collaborates closely with organisations to develop leadership capabilities that align with the demands of a rapidly evolving business landscape, ensuring sustainable success and growth. As an Independent Director, she contributes her wealth of experience and strategic guidance to the Company, playing a significant role in its development and progress.
Mr Vinod Rao is an Independent Director of the Company with effect from 29th September 2023. Currently, he is also a Director at Eureka Forbes. Mr Rao has held senior roles at renowned organisations such as Diageo (FTSE 10), PepsiCo (S&P 100), and ICI (formerly FTSE 100).
Over 35 years of expertise spans various industries, including FMCG, consumer durables, and industrial products.
Throughout his career, Mr Rao has developed a deep understanding of developing and developed markets, including India, China, Southeast Asia, the UK, and Europe. This global exposure has enabled him to navigate diverse business environments and contribute valuable insights to organisations operating in different regions.
Dr Sudhir Kumar Singh is the Chief Executive Officer of the Company. He was appointed on 29th September 2023 as the Whole-Time Chief Executive Officer of the Company. He is responsible for the Company's overall business and reports to the Company's Board of Directors.
Dr Singh's academic background includes a PhD in Medicinal Chemistry from one of India’s premier research organisations, Central Drug Research Institute, followed by a post-A doctoral fellowship in the USA and a faculty member at Rutgers University, New Jersey, with over three decades of experience in the pharmaceutical and biotech industry. Served as the Chief Operating Officer at Aragen Life Sciences Ltd., Dr Singh led a team of 2000 scientists in India's largest Contract Development and Manufacturing Organization (CDMO). His strategic guidance and exceptional project management have driven the organisation's growth and success.
With a strong drug discovery and development background, evidenced by his significant research contributions and patented innovations, Dr Singh has played a crucial role in advancing drug development efforts within the industry.
Mr Gaurav Bahadur is the Chief Human Resources Officer of the company. He was appointed on 29 September 2023. He is responsible for overseeing and managing various aspects of the human resources function within the company.
Gaurav has held leadership roles in renowned companies such as Vodafone Essar, Yahoo! India, and Philips India. His transformative tenure at Sanofi India, where he spearheaded strategic HR initiatives, showcases his expertise in building performance-driven cultures. Gaurav holds a Master’s Degree in Personnel Management from Symbiosis Institute of Business Management and a Bachelor's Degree in Chemistry from St. Xavier's College, Mumbai. Join us in welcoming Gaurav Bahadur to our team.
Mr Raju Komaravolu is the Chief Strategy Officer of the Company. He was appointed in September 2023. He is responsible for the Company's overall Strategic choice-making, Investor Relations, M&A Integration, Strategic Marketing and Transformation agenda.
Raju has a B Tech from NIT Warangal and an MBA from IIM Ahmedabad and has worked for ITC Ltd, McKinsey & Co. and Dr Reddy’s Labs Ltd.
Raju brings over 26 years of multi-industry experience across Strategy, Sales, Marketing, Manufacturing, and Project Management. Raju held several P&L leadership roles during the last five years at Dr Reddy’s. His leadership strengths lie in strategy development and strong execution.
Mr Brian Shaughnessy is the Chief Commercial Officer of the Company. Brian is responsible for leading and managing all aspects of the Company’s commercial initiatives and activities, including sales, marketing, and business development functions.
Brian has a BS in Chemical Engineering from Villanova University and has 20+ years of experience in the CDMO and life science industries. He has held various positions of increasing responsibility with companies, including Aragen (formerly GVK BIO), Piramal, Dr Reddy’s, and Johnson Matthey.
Brian is passionate about developing highly motivated teams that focus on cultivating trusted relationships with client partners by providing reliable and value-added solutions.
World class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Pharma Companies for New Chemical Entities (NCE’s) as the thrust area.